J&J is launching something called CareAdvantage which it says will help EMEA healthcare providers to deliver the holy grail of better outcomes, more satisfied patients and reduced costs. By leveraging all its hard-earned muscle, J&J could also be shoring up its customer base by establishing a gigantic barrier to entry for its competitors. Clever.
The buzz words and phrases are all here, the main one being “value-based healthcare” which is an interesting concept, given the years over which companies and healthcare providers have said they strive to do exactly that. Who wouldn’t sign up to something that purports to squeeze the metaphorical value pips out of expensive procedures? The aim is to deliver on all the three fundamentals of outcome, patient satisfaction and cost, wrapping up a sort of consulting-led supply of J&J solutions in a vehicle it’s calling CareAdvantage.
Johnson & Johnson Family Member, Johnson & Johnson Medical Devices (JJMD) says it is leveraging its 130 years of knowledge and expertise in what it says is a new approach. CareAdvantage purports to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA).
In essence, JJMD says this is a “data-driven, holistic approach involving the company partnering with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.”
The four key areas covered by the programme are:
1. Improving the patient experience: Tailored programs to support patients and healthcare professionals with comprehensive disease management, helping guide the coordination of care, standardize key practices, and engage patients throughout their health journey.
2. Driving supply chain efficiencies: Focusing on customer needs, to build solutions that streamline resources, workflows, and processes, to maintain quality whilst saving both time and costs.
3. Building clinical partnerships: Working side-by-side with healthcare partners to develop research, real world evidence, and economic validation while delivering state-of-the-art education.
4. Providing commercial support: A range of flexible programs, from consulting to implementation and outcomes, based on our shared investments and goals. These are designed to evolve with the marketplace and support hospitals to understand the broader context of their needs.
What that really means is that the company will be offering to help with many of the things that were hitherto left to healthcare providers and systems. It’s clever, not least because healthcare providers undeniably need help and JJMD has the resources and experience to provide it. Couple that with the will to continue selling its products, and everyone’s a winner, especially when JJMD will no doubt enjoy protecting its own commercial interests through what is clearly a value-adding intitiative.
“We understand our customers need support that is tailored to their specific set of circumstances – and that is exactly what CareAdvantage provides,” said Michelle Brennan, Company Group Chair, JJMD EMEA. “We have the benefit of drawing on the incredible depth of knowledge and capabilities that exists within the Johnson & Johnson healthcare network and we work together with our hospital partners to co-create measurable programs that will deliver on their strategic priorities.”
Explaining more about the approach, Hugo Breda, Vice President Strategic Capabilities, JJMD EMEA said, “We believe that solving starts with listening. CareAdvantage begins with a structured and in-depth assessment based on performance data and insights. Gathering this information and context is fundamental to the CareAdvantage approach, and helps ensure our solutions deliver value at every point along the care pathway.”
Source: Johnson and Johnson Medical Devices